Trial · NCT04480554
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
NCT04480554, Phase 2, Terminated, University of Pennsylvania
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1. Trials, record NCT04480554. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04480554
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
- NCT number
- NCT04480554
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 78 participants, actual
- Lead sponsor
- University of Pennsylvania
- Conditions
- Opioid-use Disorder, HIV-1-infection, Immune Activation, Inflammation, Methadone, Buprenorphine, Naltrexone, Antiretroviral Treatment
- Interventions
- Methadone, Buprenorphine/naloxone, XR-Naltrexone
- First posted
- 2020-07-21
- Last updated
- 2026-04-07
Source ClinicalTrials.gov
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in sCD14 | Baseline, Week-4, -8, -12, -24 | Change in plasma sCD14 concentration over 24 weeks |
| Secondary | Marker of Immune Activation: Change in CD38 | baseline, Week-4, -8, -12, -24 | Change in CD38 concentration over 24 weeks |
| Secondary | Marker of Immune Activation: HLA-DR | baseline, Week-4, -8, -12, -24 | Change in HLA-DR concentration over 24 weeks |
| Secondary | Marker of Immune Activation: Change in PD1 | baseline, Week-4, -8, -12, -24 | Change in PD1 expression in C8+ T cells over 24 weeks |
| Secondary | Marker of Immune Activation: Change in CD169 | baseline, Week-4, -8, -12, -24 | Change in CD169 expression in monocytes over 24 weeks |
| Secondary | Marker of Immune Activation: Change in sCD163 | baseline, Week-4, -8, -12, -24 | Change in plasma sCD163 concentration over 24 weeks |
| Secondary | Marker of Immune Activation: Change in Type-I IFN | baseline, week -12, -24 | Change in type-I IFN signature over 24 weeks |
| Secondary | Marker of Inflammation: Change in Plasma Hr-CRP | baseline, Week-4, -8, -12, -24 | Change in plasma hr-CRP concentration over 24 weeks |
| Secondary | Marker of Inflammation: Change in D-dimer | baseline, Week-4, -8, -12, -24 | Change in plasma d-dimer concentration over 24 weeks |
| Secondary | Marker of Inflammation: Change in sTNFR-1 | baseline, Week-4, -8, -12, -24 | Change in plasma sTNFR-1 concentration over 24 weeks |
1 to 10 of 25Source ClinicalTrials.gov
See all 25 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01DA048728 | Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment | MONTANER, LUIS J; METZGER, DAVID S | WISTAR INSTITUTE | NATIONAL INSTITUTE ON DRUG ABUSE | 2019 to 2023 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04480554
GET https://conductscience.org/api/trials/v1/NCT04480554/registered?page=2